Harold Dvorak : Peregrine Pharmaceuticals KOL : NYAS June 19-20
June 19 - 20, 2014 Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy Keynote Speaker: Harold F. Dvorak (Beth Israel Deaconess Medical Center)
This conference will examine issues in anti-angiogenic cancer therapy such as: (i) inherent / acquired resistance, (ii) immunemodulation (iii) enhanced invasiveness, and (iv) lack of validated predictive and prognostic biomarkers. Presentations, including a keynote lecture by Harold F. Dvorak, MD, will explore VEGF-dependent and alternative mechanisms of angiogenesis. Expert "point–counter point" debates will aim to resolve controversies regarding vascular normalization, treatment-induced metastasis, and the validity of hypertension as a physiological biomarker.
..earlier on June 9th, we have James Allison from MD Anderson speaking at NYAS:
Monday, June 9, 2014 | 10:00 AM - 3:15 PM 2014 Ross Prize in Molecular Medicine: Advances in Immunomodulation Featured Speakers: John J. O'Shea (National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH), James P. Allison (The University of Texas MD Anderson Cancer Center), Louis M. Staudt (National Cancer Institute, National Institutes of Health), Charles A. Dinarello (University of Colorado at Denver)
This symposium will honor Dr. John O'Shea, the recipient of the 2014 Ross Prize in Molecular Medicine, in recognition of his discoveries in immunology and cytokine biology.
Market Data 
Markets 
AI
